期刊文献+

金玉康胶囊治疗轻、中度抑郁症的Ⅱ期临床研究 被引量:3

The second phase clinical trials of Jinyukang in the treatment of mild to moderate depressive disorders
在线阅读 下载PDF
导出
摘要 目的评价金玉康胶囊治疗轻中度抑郁症的临床疗效和安全性。方法对符合CCMD-3抑郁症诊断标准的59例抑郁症患者进行金玉康胶囊和氟西汀治疗的对照研究,其中金玉康胶囊组30例(600mg/d),氟西汀组29例(20mg/d),共治疗6周。采用汉密顿抑郁量表(HAMD),汉密顿焦虑量表(HAMA),临床总体评定量表(CGI)评定临床疗效,不良事件量表评定安全性。结果经6周治疗后,金玉康胶囊组总有效率为73.33%,氟西汀组为75.86%,两组比较差异无显著性(P>0.05)。两组的HAMD,HAMA评分治疗前后比较差异有极显著性(P<0.001)。两组药物不良反应的发生率无显著性差异(P>0.05)。结论金玉康胶囊治疗轻中度抑郁症疗效好,不良反应少而轻,适合临床应用。 Objective To determine the efficacy and safety of Jinyukang for the patients with mild to moderate depressive disorders. Methods A total of 30 patients were treated with Jinyukang(600mg/d)and 29 patients were treated with fluoxetine (20mg/d)for 6 weeks. The efficacy were assessed by Hamilton Depressi'on Rating Scale(HAMD), Hamilton Anxiety Scale(HAMA), Clinical Global Impression (CGI) and the safety was assessed by Adverse Event Scale. Results After six weeks treatment, the improvement rates of Jinyukang group and fluoxetine group were 73.33% and 75.86% ,there was no difference between two groups (P〉0.05). The scores of HAMD and HAMA in two groups significantly decreased after treatment (P〈0. 001). The main adverse events of two groups were nausea, dry mouth, insomnia , et al. There was no significant difference in incidence of adverse events between Jinyukang group and fluoxetine group. Conclusion Jinyukang is an effective antidepressant with less side effects and better safety.
出处 《精神医学杂志》 2007年第5期267-270,共4页 Journal of Psychiatry
关键词 抑郁症 金玉康 氟西汀 贯叶连翘 Depression Jinyukang Fluoxetine Hypericum Perforatum
  • 相关文献

参考文献21

  • 1张筱,卢定强,权静,李晖,韦萍.贯叶连翘抗抑郁研究新进展[J].生物加工过程,2004,2(1):11-15. 被引量:32
  • 2[2]KlusaV,GermaneS,NodnerM,et al.Hypericum extractand hyperfoin::memory-enhancing properties inrodents[J].Pharmacopsychiatry,2001,34 (1):61~69
  • 3[3]DiMatteo V,DiGiovanni G.Effect of acute administration of hypericum perforatum CO2extract on dopamine and serotonin release in the rat central nervous system[J].Pharmacopsychiatry,2000,(1):14~18
  • 4[4]Wonnemann M,Singer A,Siebert B,et al.Evaluation of synaptosomal uptake inhibition of mostrelevant constituents of St.John' sWort[J].Pharmacopsychiatry,2001,34 (1):141~158
  • 5[5]Schulte L S,Holoubek G,Muller W E,et al.Comparison of the synaptosomal uptake inhibition of serotonin by St John's wort products[J].J Pharm Pharmacol,2004,56(6):813~818
  • 6[6]Friede M,Henneicke yon Zepelin H H,Freudenstein J.Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St.John's wort[J].Pharmacopsychiatry,2001,34 (1):38~41
  • 7[7]Hammerness P,Basch E,Ulbricht C,et al.St John's wort:a systematic review of adverse effects and drug interactions for the consultation psychiatrist[J].Psychosomatics,2003,44(4):271~282
  • 8[8]Muller D,Pfeil T,Vonden-Driesch V.Treating depression comorbid with anxiety-results of an open,practice-oriented study with St John's wort WS 5572 and valerian extract in high doses[J].Phytomedicine,2003,10(4):25~30
  • 9[9]Szegedi A,Konnen R,Dienel A,et al.Acute treatment of moderate to severe depression with hypericum extract WS5570(St.John's Wort):randomized controlled double-blind non-inferiority trial versus paroxetine[J].BMJ,2005,330:503~507
  • 10[10]Roder C,Schaefer M,Leucht S.Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St.John's Wort[J].Fortschr Neurol Psychiatr,2004,72(6):330~343

二级参考文献29

  • 1[1]Di Matteo V, Di Giovanni G. Effect of acute administration of hypericum perforatum-CO2 extract on dopamine and serotonin release in the rat central nervous system[ J ]. Pharmcopsychiatry, 2000, ( 1 ): 14-18.
  • 2[2]Wurgtic M, Westerhoff K, Kaunzinger A, et al. Batch-to-batch reproducibility of St. John' s wort preparations [ J ]. Pharmacopsychiatry,2001, ( 1 ): 152-156.
  • 3[3]Wenki Li,John F,F Fitzloff. High pefformanceLiquid chromatographic analysis of St. John's wort with photodiode array detection[J]. Journal of Chromatography,2001,765(B) :99-105.
  • 4[5]Klusa V, Genrmane S, Nodner M, et al. Hyper-icum extract and hyperfoin: memory-enhancing properties in rodents [ J ]. Pharmacopsychiatry,2001,34(1):61-69.
  • 5[6]Linde K, Ramirez G, et al. St. John's wort for depression-an overview and meta-analysis of randomized clinical trials [ J ]. British Medical Journal, 1996,313:253-258.
  • 6[7]Wheatley D. LI 160 an extract of St. John' s wort versus amitriptyline in mildly to mode-rately depressed outpatients-a controlled 6-week clinical trial[J]. Pharmacopsychiatry, 1997,30(2) :77-80.
  • 7[8]Vorbach E U,Amoldt K H, Hübner W D. Efficacy and tolerability of St. John' s wort extract LI 160 versus imipramine in patients with severedepressive episodes according to ICD-10 [ J ]. Pharmacopsychiatry,1997,30(1) :81-85.
  • 8[9]Brenner R, Azbel V, Madhusoodanan S, et al. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double blind,randomized pilot study. Clinical[C]. Clin Ther,2002,22(4) :411-419.
  • 9[10]Chatterjee S S, Bhattacharya S K, Wounemann M, et al. Hypefforin as a possible antidepressant component of hypericum extracts [ J ]. Life Science, 1998,63:499-510.
  • 10[11]Biber A, Fischer H, Romer A, et al. Oral bioavailability of hypefforin fromhypericum extracts in rat and human volunteers [ J ]. Pharmacopsychiatry, 1998,31 ( 1 ): 36-43.

共引文献94

同被引文献11

引证文献3

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部